TESARO, Inc. (TSRO) Director Sells $1,171,300.00 in Stock
TESARO, Inc. (NASDAQ:TSRO) Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $117.13, for a total value of $1,171,300.00. Following the completion of the sale, the director now directly owns 10,000 shares in the company, valued at approximately $1,171,300. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
TESARO, Inc. (NASDAQ:TSRO) opened at 119.04 on Friday. TESARO, Inc. has a 52 week low of $96.52 and a 52 week high of $192.94. The stock’s market capitalization is $6.45 billion. The firm has a 50-day moving average price of $121.03 and a 200-day moving average price of $138.94.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The company had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same quarter last year, the company earned ($1.28) earnings per share. The company’s revenue for the quarter was down 17.6% on a year-over-year basis. Equities research analysts predict that TESARO, Inc. will post ($8.61) EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of TSRO. BlackRock Inc. raised its position in TESARO by 4,504.8% during the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock valued at $524,643,000 after purchasing an additional 3,335,611 shares during the period. Janus Henderson Group PLC purchased a new stake in TESARO during the second quarter valued at approximately $100,301,000. PointState Capital LP purchased a new stake in TESARO during the second quarter valued at approximately $85,971,000. TIAA CREF Investment Management LLC raised its position in TESARO by 167.9% during the first quarter. TIAA CREF Investment Management LLC now owns 367,519 shares of the biopharmaceutical company’s stock valued at $56,550,000 after purchasing an additional 230,353 shares during the period. Finally, Pioneer Investment Management Inc. raised its position in TESARO by 195.6% during the second quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock valued at $44,441,000 after purchasing an additional 210,273 shares during the period.
Several analysts have weighed in on TSRO shares. ValuEngine raised TESARO from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $199.00 price target on TESARO and gave the company a “buy” rating in a report on Sunday, June 4th. Cann reaffirmed a “buy” rating and issued a $199.00 price target on shares of TESARO in a report on Monday, June 5th. FBR & Co lowered their price target on TESARO from $200.00 to $195.00 and set a “mkt perform” rating on the stock in a report on Monday, June 5th. Finally, Wedbush raised TESARO to an “outperform” rating and set a $168.00 price objective on the stock in a report on Monday, June 5th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $171.42.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.